Generali Investments CEE’s Novo Nordisk NVO Stock Holding History

Generali Investments CEE’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$697K	Sell	14,533 -2,880	-17%	-$124K	0.03%	329
2026 Q1	$640K	Sell	17,413 -4,062	-19%	-$192K	0.03%	329
2025 Q4	$1.09M	Buy	21,475 +4,533	+27%	+$232K	0.08%	239
2025 Q3	$940K	Buy	16,942 +2,000	+13%	+$117K	0.07%	244
2025 Q2	$1.03M	Hold	14,942	–	–	0.08%	223
2025 Q1	$1.04M	Buy	14,942 +2,000	+15%	+$165K	0.1%	217
2024 Q4	$1.11M	Buy	+12,942	New	+$1.4M	0.11%	195

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Generali Investments CEE's NVO Position: Q2 2026 in Review

Generali Investments CEE reduced its Novo Nordisk (NVO) stake by 17% in Q2 2026, selling an estimated $124K and leaving 14,533 shares worth $697K. The position accounts for 0.03% of the portfolio, ranked #329.

Generali Investments CEE first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.11M in Q4 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Generali Investments CEE held 14,533 shares of Novo Nordisk worth $697K as of Q2 2026.
Generali Investments CEE sold 2,880 Novo Nordisk shares in Q2 2026, an estimated $124K.
Novo Nordisk made up 0.03% of Generali Investments CEE's portfolio in Q2 2026, its #329 holding.
Generali Investments CEE first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
Generali Investments CEE's Novo Nordisk position peaked at $1.11M in Q4 2024.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Generali Investments CEE's 13F filing for Q2 2026, filed 13 Jul 2026.